Lentiviral vectors and cardiovascular diseases: A genetic tool for manipulating cardiomyocyte differentiation and function

Gene Therapy

Volumn 19, Issue 6, 2012, Pages 642-648

  Di Pasquale, E ^a,b   Latronico, M V G ^c   Jotti, G S ^d   Condorelli, G ^e  

^a IRCCS MULTIMEDICA   (Italy)

^b UOS Milan   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d UNIVERSITY OF PARMA   (Italy)

^e CNR   (Italy)

Author keywords

cardiomyocytes; cell tracking; heart; iPS cells; lentiviral vectors; reprogramming strategies

Indexed keywords

ALPHA GALACTOSIDASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LENTIVIRUS VECTOR; PRODYNORPHIN; RECOMBINANT SOMATOMEDIN C; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR SOX2;

CARDIAC PROGENITOR CELL; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL FATE; CELL FUNCTION; CELL LINEAGE; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSDIFFERENTIATION; CELL TRANSPLANTATION; DNA MODIFICATION; DRUG EFFECT; EMBRYONIC STEM CELL; FABRY DISEASE; GENE EXPRESSION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HOMOLOGOUS RECOMBINATION; HUMAN; NONHUMAN; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION; TARGET CELL; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE;

CARDIOVASCULAR DISEASES; CELL DIFFERENTIATION; CELL TRANSDIFFERENTIATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LENTIVIRUS; MYOCYTES, CARDIAC;

IPS; LENTIVIRUS; MAMMALIA;

EID: 84862004322     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2012.19     Document Type: Review

References (75)

1. Lyon AR, Sato M, Hajjar RJ, Samulski RJ, Harding SE. Gene therapy: targeting the myocardium. Heart 2008; 94: 89-99.
2. Blomer U, Gruh I, Witschel H, Haverich A, Martin U. Shuttle of lentiviral vectors via transplanted cells in vivo. Gene Therapy 2005; 12: 67-74. (Pubitemid 40090046)
3. Bonci D, Cittadini A, Latronico MV, Borello U, Aycock JK, Drusco A et al. Advanced¢ generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo. Gene Therapy 2003; 10: 630-636. (Pubitemid 36553608)
4. Naldini L. Lentiviruses as gene transfer agents for delivery to non-dividing cells. Curr Opin Biotechnol 1998; 9: 457-463. (Pubitemid 28478965)
5. Naldini L, Blomer U, Gage FH, Trono D, Verma IM. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996; 93: 11382-11388. (Pubitemid 26347130)
6. Sakoda T, Kasahara N, Hamamori Y, Kedes L. A high-titer lentiviral production system mediates efficient transduction of differentiated cells including beating cardiac myocytes. J Mol Cell Cardiol 1999; 31: 2037-2047. (Pubitemid 29537603)
7. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-8471. (Pubitemid 28471781)
8. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267. (Pubitemid 26119138)
9. Matrai J, Chuah MK, VandenDriessche T. Recent advances in lentiviral vector development and applications. Mol Ther 2010; 18: 477-490.
10. Sinn PL, Sauter SL, McCray Jr. PB. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors-design, biosafety, and production. Gene Therapy 2005; 12: 1089-1098. (Pubitemid 41030614)
11. Gai H, Leung EL, Costantino PD, Aguila JR, Nguyen DM, Fink LM et al. Generation and characterization of functional cardiomyocytes using induced pluripotent stem cells derived from human fibroblasts. Cell Biol Int 2009; 33: 1184-1193.
12. Mauritz C, Schwanke K, Reppel M, Neef S, Katsirntaki K, Maier LS et al. Generation of functional murine cardiac myocytes from induced pluripotent stem cells. Circulation 2008; 118: 507-517.
13. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282: 1145-1147. (Pubitemid 28516247)
14. Laflamme MA, Murry CE. Heart regeneration. Nature 2011; 473: 326-335.
15. Murry CE, Keller G. Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell 2008; 132: 661-680. (Pubitemid 351260059)
16. Leschik J, Stefanovic S, Brinon B, Puceat M. Cardiac commitment of primate embryonic stem cells. Nat Protoc 2008; 3: 1381-1387.
17. Yang L, Soonpaa MH, Adler ED, Roepke TK, Kattman SJ, Kennedy M et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell- derived population. Nature 2008; 453: 524-528. (Pubitemid 351733312)
18. Hidaka K, Lee JK, Kim HS, Ihm CH, Iio A, Ogawa M et al. Chamber-specific differentiation of Nkx2.5-positive cardiac precursor cells from murine embryonic stem cells. FASEB J 2003; 17: 740-742.
19. Klug MG, Soonpaa MH, Koh GY, Field LJ. Genetically selected cardiomyocytes from differentiating embronic stem cells form stable intracardiac grafts. J Clin Invest 1996; 98: 216-224. (Pubitemid 26243839)
20. Kolossov E, Fleischmann BK, Liu Q, Bloch W, Viatchenko-Karpinski S, Manzke O et al. Functional characteristics of ES cell-derived cardiac precursor cells identified by tissue-specific expression of the green fluorescent protein. J Cell Biol 1998; 143: 2045-2056. (Pubitemid 29022623)
21. Muller M, Fleischmann BK, Selbert S, Ji GJ, Endl E, Middeler G et al. Selection of ventricular-like cardiomyocytes from ES cells in vitro. FASEB J 2000; 14: 2540-2548.
22. Schroeder M, Niebruegge S, Werner A, Willbold E, Burg M, Ruediger M et al. Differentiation and lineage selection of mouse embryonic stem cells in a stirred bench scale bioreactor with automated process control. Biotechnol Bioeng 2005; 92: 920-933.
23. Zwaka TP, Thomson JA. Homologous recombination in human embryonic stem cells. Nat Biotechnol 2003; 21: 319-321. (Pubitemid 36314818)
24. Bai X, Yan Y, Coleman M, Wu G, Rabinovich B, Seidensticker M et al. Tracking longterm survival of intramyocardially delivered human adipose tissue-derived stem cells using bioluminescence imaging. Mol Imaging Biol 2011; 13: 633-645.
25. Huber I, Itzhaki I, Caspi O, Arbel G, Tzukerman M, Gepstein A et al. Identification and selection of cardiomyocytes during human embryonic stem cell differentiation. FASEB J 2007; 21: 2551-2563. (Pubitemid 47230684)
26. Kita-Matsuo H, Barcova M, Prigozhina N, Salomonis N, Wei K, Jacot JG et al. Lentiviral vectors and protocols for creation of stable hESC lines for fluorescent tracking and drug resistance selection of cardiomyocytes. PLoS One 2009; 4: e5046.
27. Gallo P, Grimaldi S, Latronico MV, Bonci D, Pagliuca A, Ausoni S et al. A lentiviral vector with a short troponin-I promoter for tracking cardiomyocyte differentiation of human embryonic stem cells. Gene Therapy 2008; 15: 161-170. (Pubitemid 351150040)
28. Gruh I, Wunderlich S, Winkler M, Schwanke K, Heinke J, Blomer U et al. Human CMV immediate-early enhancer: a useful tool to enhance cell-type-specific expression from lentiviral vectors. J Gene Med 2008; 10: 21-32.
29. Altomare C, Barile L, Marangoni S, Rocchetti M, Alemanni M, Mostacciuolo G et al. Caffeine-induced Ca(2+) signaling as an index of cardiac progenitor cells differentiation. Basic Res Cardiol 2010; 105: 737-749.
30. Rizzi R, Di Pasquale E, Portararo P, Papait R, Cattaneo P, Latronico MV et al. Post-natal cardiomyocytes can generate iPS cells with an enhanced capacity toward cardiomyogenic re-differentation. Cell Death Differ 2012; e-pub ahead of print 20. January 2012; doi: 10.1038/cdd.2011.205.
31. Bai X, Pinkernell K, Song YH, Nabzdyk C, Reiser J, Alt E. Genetically selected stem cells from human adipose tissue express cardiac markers. Biochem Biophys Res Commun 2007; 353: 665-671. (Pubitemid 46048721)
32. Barth AS, Kizana E, Smith RR, Terrovitis J, Dong P, Leppo MK et al. Lentiviral vectors bearing the cardiac promoter of the Na+-Ca2+ exchanger report cardiogenic differentiation in stem cells. Mol Ther 2008; 16: 957-964. (Pubitemid 351587107)
33. Higuchi K, Yoshimitsu M, Fan X, Guo X, Rasaiah VI, Yen J et al. Alpha-galactosidase A-Tat fusion enhances storage reduction in hearts and kidneys of Fabry mice. Mol Med 2010; 16: 216-221.
34. Lee CJ, Fan X, Guo X, Medin JA. Promoter-specific lentivectors for long-term, cardiacdirected therapy of Fabry disease. J Cardiol 2011; 57: 115-122.
35. Dong F, Khalil M, Kiedrowski M, O¢Connor C, Petrovic E, Zhou X et al. Critical role for leukocyte hypoxia inducible factor-1alpha expression in post-myocardial infarction left ventricular remodeling. Circ Res 2010; 106: 601-610.
36. Gupta S, Maitra R, Young D, Gupta A, Sen S. Silencing the myotrophin gene by RNA interference leads to the regression of cardiac hypertrophy. Am J Physiol Heart Circ Physiol 2009; 297: H627-H636.
37. Koyanagi M, Iwasaki M, Rupp S, Tedesco FS, Yoon CH, Boeckel JN et al. Sox2 transduction enhances cardiovascular repair capacity of blood-derived mesoangioblasts. Circ Res 2010; 106: 1290-1302.
38. Maioli M, Asara Y, Pintus A, Ninniri S, Bettuzzi S, Scaltriti M et al. Creating prodynorphin-expressing stem cells alerted for a high-throughput of cardiogenic commitment. Regen Med 2007; 2: 193-202. (Pubitemid 46831080)
39. Niwano K, Arai M, Koitabashi N, Watanabe A, Ikeda Y, Miyoshi H et al. Lentiviral vector-mediated SERCA2 gene transfer protects against heart failure and left ventricular remodeling after myocardial infarction in rats. Mol Ther 2008; 16: 1026-1032. (Pubitemid 351737066)
40. Port JD, Bristow MR. beta-Adrenergic receptors, transgenic mice, and pharmacological model systems. Mol Pharmacol 2001; 60: 629-631. (Pubitemid 32900242)
41. Hoshijima M. Gene therapy targeted at calcium handling as an approach to the treatment of heart failure. Pharmacol Ther 2005; 105: 211-228. (Pubitemid 40292723)
42. Eckle T, Kohler D, Lehmann R, El Kasmi K, Eltzschig HK. Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation 2008; 118: 166-175.
43. del Monte F, Harding SE, Dec GW, Gwathmey JK, Hajjar RJ. Targeting phospholamban by gene transfer in human heart failure. Circulation 2002; 105: 904-907. (Pubitemid 34184564)
44. del Monte F, Harding SE, Schmidt U, Matsui T, Kang ZB, Dec GW et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation 1999; 100: 2308-2311.
45. Maurice JP, Hata JA, Shah AS, White DC, McDonald PH, Dolber PC et al. Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary beta2-adrenergic receptor gene delivery. J Clin Invest 1999; 104: 21-29. (Pubitemid 29534341)
46. Shah AS, Lilly RE, Kypson AP, Tai O, Hata JA, Pippen A et al. Intracoronary adenovirus-mediated delivery and overexpression of the beta(2)-adrenergic receptor in the heart : prospects for molecular ventricular assistance. Circulation 2000; 101: 408-414. (Pubitemid 30067398)
47. Heine HL, Leong HS, Rossi FM, McManus BM, Podor TJ. Strategies of conditional gene expression in myocardium: an overview. Methods Mol Med 2005; 112: 109-154.
48. Vigna E, Cavalieri S, Ailles L, Geuna M, Loew R, Bujard H et al. Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors. Mol Ther 2002; 5: 252-261. (Pubitemid 34211220)
49. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872. (Pubitemid 350138099)
50. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676. (Pubitemid 44233629)
51. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-1920.
52. Hanna JH, Saha K, Jaenisch R. Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues. Cell 2010; 143: 508-525.
53. Stadtfeld M, Hochedlinger K. Induced pluripotency: history, mechanisms, and applications. Genes Dev 2010; 24: 2239-2263.
54. Yamanaka S. A fresh look at iPS cells. Cell 2009; 137: 13-17.
55. Josowitz R, Carvajal-Vergara X, Lemischka IR, Gelb BD. Induced pluripotent stem cell-derived cardiomyocytes as models for genetic cardiovascular disorders. Curr Opin Cardiol 2011; 26: 223-229.
56. Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A et al. Disease-specific induced pluripotent stem cells. Cell 2008; 134: 877-886.
57. Carvajal-Vergara X, Sevilla A, D¢Souza SL, Ang YS, Schaniel C, Lee DF et al. Patientspecific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 2010; 465: 808-812.
58. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flugel L et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 2010; 363: 1397-1409.
59. Yazawa M, Hsueh B, Jia X, Pasca AM, Bernstein JA, Hallmayer J et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 2011; 471: 230-234.
60. Zou J, Maeder ML, Mali P, Pruett-Miller SM, Thibodeau-Beganny S, Chou BK et al. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell 2009; 5: 97-110.
61. Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Sudhof TC, Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010; 463: 1035-1041.
62. Szabo E, Rampalli S, Risueno RM, Schnerch A, Mitchell R, Fiebig-Comyn A et al. Direct conversion of human fibroblasts to multilineage blood progenitors. Nature 2010; 468: 521-526.
63. Ieda M, Fu JD, Delgado-Olguin P, Vedantham V, Hayashi Y, Bruneau BG et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010; 142: 375-386.
64. Jacome A, Navarro S, Rio P, Yanez RM, Gonzalez-Murillo A, Lozano ML et al. Lentiviralmediated genetic correction of hematopoietic and mesenchymal progenitor cells from Fanconi anemia patients. Mol Ther 2009; 17: 1083-1092.
65. Marangoni F, Bosticardo M, Charrier S, Draghici E, Locci M, Scaramuzza S et al. Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models. Mol Ther 2009; 17: 1073-1082.
66. Zhao H, Pestina TI, Nasimuzzaman M, Mehta P, Hargrove PW, Persons DA. Amelioration of murine beta-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both gamma-globin and the MGMT drug-resistance gene. Blood 2009; 113: 5747-5756.
67. Connolly JB. Lentiviruses in gene therapy clinical research. Gene Therapy 2002; 9: 1730-1734.
68. Woods NB, Muessig A, Schmidt M, Flygare J, Olsson K, Salmon P et al. Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis. Blood 2003; 101: 1284-1289. (Pubitemid 36182497)
69. Ly H, Kawase Y, Yoneyama R, Hajjar RJ. Gene therapy in the treatment of heart failure. Physiology (Bethesda) 2007; 22: 81-96.
70. Bouard D, Alazard-Dany D, Cosset FL. Viral vectors: from virology to transgene expression. Br J Pharmacol 2009; 157: 153-165.
71. Bank A, Dorazio R, Leboulch P. A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia. Ann NY Acad Sci 2005; 1054: 308-316. (Pubitemid 43031038)
72. Cartier N, Aubourg P. Hematopoietic stem cell gene therapy in Hurler syndrome, globoid cell leukodystrophy, metachromatic leukodystrophy and X-adrenoleukodystrophy. Curr Opin Mol Ther 2008; 10: 471-478.
73. Isacson O, Kordower JH. Future of cell and gene therapies for Parkinson¢s disease. Ann Neurol 2008; 64 (Suppl 2): S122-S138.
74. Kaiser J. Gene therapy. Beta-thalassemia treatment succeeds, with a caveat. Science 2009; 326: 1468-1469.
75. Dropulic B. Lentiviral vectors: their molecular design, safety, and use in laboratory and preclinical research. Hum Gene Ther 2011; 22: 649-657.